Single Sales/Supply Contract
CAI summary · Not investment advice
Curiox Biosystems terminated an equipment sales contract worth KRW 2.72 billion with its Chinese subsidiary on October 29, 2026.
Contract amount
KRW 2.7 billion
Key facts
- Recent revenue
- KRW 7.2 billionRevenue for 2022
- % of revenue
- 37.60%
- Counterparty
- Curiox Biosystems China Co., Ltd.
- Contract details
- Sales contract for HT and Buffer Exchanger equipment
- Contract period
- Nov 1, 2023 – Oct 31, 2026
Commentary
AI commentary · Not investment advice
What happened
Curiox Biosystems terminated its contract with Curiox Biosystems China Co., Ltd. for the sale of HT and Buffer Exchanger equipment on October 29, 2026. The contract was worth KRW 2.7 billion and ran from November 1, 2023 to October 31, 2026. The stated reason is that the company received an official letter from the main contractor, Hunan Deshengyuan Biotechnology Co., Ltd., saying the contract could not be performed.
In the company's terms
The contract amount was equal to 37.60% of the company's most recent revenue of KRW 7.2 billion. Relative to market capitalization, the filing lists 0.3%. The filing was received on October 29, 2026.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist